<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501695</url>
  </required_header>
  <id_info>
    <org_study_id>NCT00797953</org_study_id>
    <nct_id>NCT01501695</nct_id>
  </id_info>
  <brief_title>Phase III Study of 5LGr to Treat Tic Disorder</brief_title>
  <acronym>5LGr</acronym>
  <official_title>A 3-arm Phase III Study of 5LGr, Tiapride or Placebo in Pediatric Patients With Tic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tasly Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effective and safety of 5LGr in pediatric
      patients with tic disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5LGr is a kind of traditional Chinese medicine(TCM) which under the direction of TCM
      theory.The aim of this study is prove the effective and safety of 5LGr in children and
      adolescence of Tic syndrome sub-population with specific TCM syndrome differentiation, when
      compared with tiapride and placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale Global Tic Severity Scale(YGTSS) score change from baseline at 8 weeks</measure>
    <time_frame>Within 8 weeks of completion intervention.</time_frame>
    <description>The outcome will be assessed at 8th weeks. And patients who judged as effective by investigator will be included in a follow-up period up to 4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of syndrome scales from baseline at 8 weeks;</measure>
    <time_frame>Within 8 weeks of completion intervention.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of YGTSS scores from baseline at 2 weeks;</measure>
    <time_frame>within 2 weeks of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of syndrome scales from baseline at 2 weeks;</measure>
    <time_frame>Within 2 weeks of intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">603</enrollment>
  <condition>Tic Disorder</condition>
  <condition>Tourette Syndrome</condition>
  <condition>Chronic Tic Disorder</condition>
  <arm_group>
    <arm_group_label>5LGr, granule and placebo tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:5LGr; Dosage form:Granule;Strength:5 gram/sack;Mimic Tablet:0 mg/tablet. Dosage: 5LGr Granule: 1 sack, t.i.d. for patients less than 12 yrs,whereas 1.5 sacks, t.i.d. for patients 13-18 yrs.
Mimic tablet:For patients 5-12 yrs: 0.5 tablet, b.i.d for first 2 weeks, then 1 tablet, bid for next 6 weeks; for patients 13-18 yrs: tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.
Duration: 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiapride tabletand mimic 5LGr granule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiapride are 100 mg scored tablets. Mimic 5LGr granule are preparation that contain no active ingredient, and act as placebo.
Dosage: Tiaptride tablet: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.
Mimic 5LGr Granule:Strength:0 gram/sack.Dosage:1 sack for patients less than 12 yrs,while 1.5 sacks for patients 13-18 yrs.Frequency: T.i.d.
Duration: 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, granule and tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm includes mimic preparation of 5LGr granule and tiapride tablets , which doesn't contain active ingredients.
Dosage form: Mimic Granule:Strength:0 gram/sack Dosage:1 sack, t.i.d for patients less than 12 yrs,while 1.5 sacks, t.i.d for patients 13-18 yrs.
Mimic tablet:Strength:0 mg/tablet.For patients 5-12 yrs: 0.5 tablets b.i.d for first 2 weeks, then 1 tablet,b.i.d for next 6 weeks; for patients 13-18 yrs:1 tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.
Duration: 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5LGr</intervention_name>
    <description>Dosage form:Granule Strength:5 gram/sack Dosage:1 sack for patients less than 12 yrs 1.5 sacks for patients 13-18 yrs. Frequency: three times per day. Duration: 8 weeks.</description>
    <arm_group_label>5LGr, granule and placebo tablet</arm_group_label>
    <other_name>Wuling Granule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiapride</intervention_name>
    <description>dosage form: tablet Strength:100 mg Dosage: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.
Total duration:8 weeks.</description>
    <arm_group_label>tiapride tabletand mimic 5LGr granule</arm_group_label>
    <other_name>Tiapridel, Tiapridax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>mimetic granule: same with 5LGr mimetic tablet: same with tiapride</description>
    <arm_group_label>placebo, granule and tablet</arm_group_label>
    <other_name>Blank tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;1 year history of diagnosed tic disorder;

          -  age:5-18 yrs;

          -  YGTSS score&gt;=30 at baseline.

        Exclusion Criteria:

          -  Diagnosed with hyperactivity disorder,epilepsy,chorea,autism,obsessive-compulsive
             disorder,mental retardation,athetosis,Wilson's disease.

          -  Any indefinite tic disorder or tic disorders caused by medication.

          -  Participation to other studies.

          -  Patients with loose stool.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinmin Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing University of TCM affiliated hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yi zheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Minjie Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing Medical college Attached Brain Branch Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaowei Wei, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yan Cheng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Teaching Hospital of Tianjin University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xuefeng Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Hospital of Liaoning University of TCM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuyan Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang University of TCM affiliated hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ying Ding, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan University of TCM affiliated hospital</affiliation>
  </overall_official>
  <link>
    <url>http://www.tasly.com</url>
    <description>Manufacturer</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2011</study_first_submitted>
  <study_first_submitted_qc>December 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tic disorder</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Tics</mesh_term>
    <mesh_term>Tic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiapride Hydrochloride</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 10, 2015</submitted>
    <returned>March 19, 2015</returned>
    <submitted>November 16, 2015</submitted>
    <returned>December 17, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

